Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT06496568 |
| Title | A Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab in PIK3CA-Mutated Cancers |
| Recruitment | Active, not recruiting |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | Yes |
| Sponsors | Hoffmann-La Roche |
| Indications | |
| Therapies | |
| Age Groups: | senior | adult |
| Covered Countries | USA | CAN |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Vanderbilt-Ingram Cancer Ctr | Nashville | Tennessee | 37232 | United States | Details | |
| BC Cancer Vancouver Centre | Vancouver | British Columbia | V5Z 4E6 | Canada | Details | |
| Princess Margaret Cancer Center | Toronto | Ontario | M5G 2M9 | Canada | Details | |
| Jewish General Hospital | Montreal | Quebec | H3T 1E2 | Canada | Details | |
| Samsung Medical Center | Seoul | 06351 | South Korea | Details |